Type 1 Deiodinase Regulates ApoA-I Gene Expression and ApoA-I Synthesis Independent of Thyroid Hormone Signaling

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 7, 2016, Pages 1356-1366

  Liu, Jing ^a   Hernandez Ono, Antonio ^a   Graham, Mark J ^b   Galton, Valerie Anne ^c   Ginsberg, Henry N ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

apolipoprotein A I; Cholesterol HDL; Electrophoretic mobility shift assay; Knockout; Mice; Response element; Type 1 deiodinase

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A1; CRE RECOMBINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN RECEPTOR; LIOTHYRONINE; MESSENGER RNA; SMALL INTERFERING RNA; THYROID HORMONE; APOA1 PROTEIN, HUMAN; IODIDE PEROXIDASE; PROTEIN BINDING; SELENODEIODINASE TYPE 1, MOUSE;

ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENE; GENE OVEREXPRESSION; GENE SYNTHESIS; HEPG2 CELL LINE; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SECRETION; THYROID HORMONE RESPONSE ELEMENT; TYPE 1 DEIODINASE GENE; ANIMAL; BLOOD; C57BL MOUSE; DEFICIENCY; DNA RESPONSIVE ELEMENT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; GENOTYPE; HEP-G2 CELL LINE; LIVER; MALE; METABOLISM; PHENOTYPE; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; GENE EXPRESSION REGULATION; GENOTYPE; HEP G2 CELLS; HUMANS; IODIDE PEROXIDASE; LIVER; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGONUCLEOTIDES, ANTISENSE; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTOR, INSULIN; RESPONSE ELEMENTS; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION; TRIIODOTHYRONINE;

EID: 84965043303     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.307330     Document Type: Article

References (61)

1. Gofman JW, Young W, Tandy R, Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966 34 679 697
2. Gordon T, Kannel WB, Castelli WP, Dawber TR, Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981 141 1128 1131
3. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W, AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011 365 2255 2267. doi: 10.1056/NEJMoa1107579.
4. Landray MJ, Haynes R, Armitage J, Niacin for reduction of cardiovascular risk. N Engl J Med 2014 371 1943 1944. doi: 10.1056/NEJMc1411240.
5. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999 341 410 418. doi: 10.1056/NEJM199908053410604.
6. Ginsberg HN, Elam MB, Lovato LC, ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 362 1563 1574. doi: 10.1056/NEJMoa1001282.
7. Barter PJ, Caulfield M, Eriksson M, ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 2109 2122. doi: 10.1056/NEJMoa0706628.
8. Schwartz GG, Olsson AG, Abt M, dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 367 2089 2099. doi: 10.1056/NEJMoa1206797.
9. Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Nyaku M, Horvath KV, Asztalos BF, Otokozawa S, Ai M, Matthan NR, Lichtenstein AH, Dolnikowski GG, Schaefer EJ, Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008 28 1672 1678. doi: 10.1161/ATVBAHA.108.164541.
10. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM, Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991 353 265 267. doi: 10.1038/353265a0.
11. Plump AS, Scott CJ, Breslow JL, Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 1994 91 9607 9611
12. Pászty C, Maeda N, Verstuyft J, Rubin EM, Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994 94 899 903. doi: 10.1172/JCI117412.
13. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Puré E, Rader DJ, Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999 100 1816 1822
14. Borthwick F, Warnakula S, Mangat R, Uwiera RR, Russell JC, Kelly SE, Lee CY, Hryshko L, Mamo JC, Rye KA, Lopaschuk GD, Proctor SD, ApoA-1 infusion reduces arterial cholesterol and myocardial lesions in a rat model of cardiac dysfunction and insulin resistance. Atherosclerosis 2012 222 402 408. doi: 10.1016/j.atherosclerosis.2012.03.006.
15. Tardy C, Goffinet M, Boubekeur N, Ackermann R, Sy G, Bluteau A, Cholez G, Keyserling C, Lalwani N, Paolini JF, Dasseux JL, Barbaras R, Baron R, CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis 2014 232 110 118. doi: 10.1016/j.atherosclerosis.2013.10.018.
16. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003 290 2292 2300. doi: 10.1001/jama.290.17.2292.
17. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J, Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 2007 297 1675 1682. doi: 10.1001/jama.297.15.jpc70004.
18. Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, Martin BD, Perlman TJ, Maltais JA, Weissman NJ, Fitzgerald PJ, Brewer HB Jr., A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010 55 2727 2735. doi: 10.1016/j.jacc.2009.12.067.
19. Reaven GM, Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988 37 1595 1607
20. Chahil TJ, Ginsberg HN, Diabetic dyslipidemia. Endocrinol Metab Clin North Am 2006 35 491 510, vii. doi: 10.1016/j.ecl.2006.06.002.
21. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR, Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008 7 125 134. doi: 10.1016/j.cmet.2007.11.013.
22. Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, White MF, Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab 2008 8 65 76. doi: 10.1016/j.cmet.2008.06.006.
23. Schneider MJ, Fiering SN, Thai B, Wu SY, St Germain E, Parlow AF, St Germain DL, Galton VA, Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice. Endocrinology 2006 147 580 589. doi: 10.1210/en.2005-0739.
24. Galton VA, Schneider MJ, Clark AS, St Germain DL, Life without thyroxine to 3,5,3'-Triiodothyronine conversion: studies in mice devoid of the 5'-deiodinases. Endocrinology 2009 150 2957 2963. dio:10.1210/en.2008-1572
25. Galton VA, de Waard E, Parlow AF, St Germain DL, Hernandez A, Life without the iodothyronine deiodinases. Endocrinology 2014 155 4081 4087. doi: 10.1210/en.2014-1184.
26. Strobl W, Chan L, Patsch W, Differential regulation of hepatic apolipoprotein A-I and A-II gene expression by thyroid hormone in rat liver. Atherosclerosis 1992 97 161 170
27. Apostolopoulos JJ, La Scala MJ, Howlett GJ, The effect of triiodothyronine on rat apolipoprotein A-I and A-IV gene transcription. Biochem Biophys Res Commun 1988 154 997 1002
28. Berry MJ, Grieco D, Taylor BA, Maia AL, Kieffer JD, Beamer W, Glover E, Poland A, Larsen PR, Physiological and genetic analyses of inbred mouse strains with a type I iodothyronine 5' deiodinase deficiency. J Clin Invest 1993 92 1517 1528. doi: 10.1172/JCI116730.
29. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B, Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-Activated receptor with its response element. J Biol Chem 1994 269 31012 31018
30. Romney JS, Chan J, Carr FE, Mooradian AD, Wong NC, Identification of the thyroid hormone-responsive messenger RNA spot 11 as apolipoprotein-A1 messenger RNA and effects of the hormone on the promoter. Mol Endocrinol 1992 6 943 950. doi: 10.1210/mend.6.6.1495493.
31. Taylor AH, Wishart P, Lawless DE, Raymond J, Wong NC, Identification of functional positive and negative thyroid hormone-responsive elements in the rat apolipoprotein AI promoter. Biochemistry 1996 35 8281 8288. doi: 10.1021/bi960269o.
32. Malik S, Transcriptional regulation of the apolipoprotein AI gene. Front Biosci 2003 8 d360 d368
33. Ladias JA, Karathanasis SK, Regulation of the apolipoprotein AI gene by ARP-1, a novel member of the steroid receptor superfamily. Science 1991 251 561 565
34. Widom RL, Rhee M, Karathanasis SK, Repression by ARP-1 sensitizes apolipoprotein AI gene responsiveness to RXR alpha and retinoic acid. Mol Cell Biol 1992 12 3380 3389
35. Fuernkranz HA, Wang Y, Karathanasis SK, Mak P, Transcriptional regulation of the apoAI gene by hepatic nuclear factor 4 in yeast. Nucleic Acids Res 1994 22 5665 5671
36. Chan J, Nakabayashi H, Wong NC, HNF-4 increases activity of the rat Apo A1 gene. Nucleic Acids Res 1993 21 1205 1211
37. Rottman JN, Widom RL, Nadal-Ginard B, Mahdavi V, Karathanasis SK, A retinoic acid-responsive element in the apolipoprotein AI gene distinguishes between two different retinoic acid response pathways. Mol Cell Biol 1991 11 3814 3820
38. Harnish DC, Malik S, Kilbourne E, Costa R, Karathanasis SK, Control of apolipoprotein AI gene expression through synergistic interactions between hepatocyte nuclear factors 3 and 4. J Biol Chem 1996 271 13621 13628
39. Berthou L, Duverger N, Emmanuel F, Langouët S, Auwerx J, Guillouzo A, Fruchart JC, Rubin E, Denèfle P, Staels B, Branellec D, Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 1996 97 2408 2416. doi: 10.1172/JCI118687.
40. Lam JK, Matsubara S, Mihara K, Zheng XL, Mooradian AD, Wong NC, Insulin induction of apolipoprotein AI, role of Sp1. Biochemistry 2003 42 2680 2690. doi: 10.1021/bi026984h.
41. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, Fruchart JC, Dallongeville J, Hum DW, Kuipers F, Staels B, Bile acid-Activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 2002 109 961 971. doi: 10.1172/JCI14505.
42. Harnish DC, Malik S, Karathanasis SK, Activation of apolipoprotein AI gene transcription by the liver-enriched factor HNF-3. J Biol Chem 1994 269 28220 28226
43. Elshourbagy NA, Boguski MS, Liao WS, Jefferson LS, Gordon JI, Taylor JM, Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc Natl Acad Sci U S A 1985 82 8242 8246
44. Levy E, Sinnett D, Thibault L, Nguyen TD, Delvin E, Ménard D, Insulin modulation of newly synthesized apolipoproteins B-100 and B-48 in human fetal intestine: gene expression and mRNA editing are not involved. FEBS Lett 1996 393 253 258
45. Haas MJ, Pun K, Reinacher D, Wong NC, Mooradian AD, Effects of ketoacidosis on rat apolipoprotein A1 gene expression: A link with acidosis but not with ketones. J Mol Endocrinol 2000 25 129 139
46. Koenig RJ, Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid 2005 15 835 840. doi: 10.1089/thy.2005.15.835.
47. Toyoda N, Zavacki AM, Maia AL, Harney JW, Larsen PR, A novel retinoid X receptor-independent thyroid hormone response element is present in the human type 1 deiodinase gene. Mol Cell Biol 1995 15 5100 5112
48. Zhang CY, Kim S, Harney JW, Larsen PR, Further characterization of thyroid hormone response elements in the human type 1 iodothyronine deiodinase gene. Endocrinology 1998 139 1156 1163. doi: 10.1210/endo.139.3.5849.
49. Maia AL, Kieffer JD, Harney JW, Larsen PR, Effect of 3,5,3'-Triiodothyronine (T3) administration on dio1 gene expression and T3 metabolism in normal and type 1 deiodinase-deficient mice. Endocrinology 1995 136 4842 4849. dio:10.1210/endo.136.11.7588215
50. Kanamoto N, Tagami T, Ueda-Sakane Y, Sone M, Miura M, Yasoda A, Tamura N, Arai H, Nakao K, Forkhead box A1 (FOXA1) and A2 (FOXA2) oppositely regulate human type 1 iodothyronine deiodinase gene in liver. Endocrinology 2012 153 492 500. doi: 10.1210/en.2011-1310.
51. Tabata S, Nishikawa M, Toyoda N, Yonemoto T, Ogawa Y, Inada M, Effect of triiodothyronine administration on reduced expression of type 1 iodothyronine deiodinase messenger ribonucleic acid in streptozotocin-induced diabetic rats. Endocr J 1999 46 367 374
52. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR, Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000 6 87 97
53. Apostolopoulos JJ, Howlett GJ, Fidge N, Effects of dietary cholesterol and hypothyroidism on rat apolipoprotein mRNA metabolism. J Lipid Res 1987 28 642 648
54. Davidson NO, Carlos RC, Drewek MJ, Parmer TG, Apolipoprotein gene expression in the rat is regulated in a tissue-specific manner by thyroid hormone. J Lipid Res 1988 29 1511 1522
55. Hargrove GM, Junco A, Wong NC, Hormonal regulation of apolipoprotein AI. J Mol Endocrinol 1999 22 103 111
56. Go MF, Schonfeld G, Pfleger B, Cole TG, Sussman NL, Alpers DH, Regulation of intestinal and hepatic apoprotein synthesis after chronic fat and cholesterol feeding. J Clin Invest 1988 81 1615 1620. doi: 10.1172/JCI113496.
57. Cheng SY, Leonard JL, Davis PJ, Molecular aspects of thyroid hormone actions. Endocr Rev 2010 31 139 170. doi: 10.1210/er.2009-0007.
58. Christoffolete MA, Arrojo e Drigo R, Gazoni F, Tente SM, Goncalves V, Amorim BS, Larsen PR, Bianco AC, Zavacki AM, Mice with impaired extrathyroidal thyroxine to 3,5,3'-Triiodothyronine conversion maintain normal serum 3,5,3'-Triiodothyronine concentrations. Endocrinology 2007 148 954 960. dio:10.1210/en.2006-1042
59. Papazafiri P, Ogami K, Ramji DP, Nicosia A, Monaci P, Cladaras C, Zannis VI, Promoter elements and factors involved in hepatic transcription of the human ApoA-I gene positive and negative regulators bind to overlapping sites. J Biol Chem 1991 266 5790 5797
60. Novak EM, Bydlowski SP, NFY transcription factor binds to regulatory element AIC and transactivates the human apolipoprotein A-I promoter in HEPG2 cells. Biochem Biophys Res Commun 1997 231 140 143. doi: 10.1006/bbrc.1997.6056.
61. Oleaga C, Ciudad CJ, Izquierdo-Pulido M, Noé V, Cocoa flavanol metabolites activate HNF-3β Sp1, and NFY-mediated transcription of apolipoprotein AI in human cells. Mol Nutr Food Res 2013 57 986 995. doi: 10.1002/mnfr.201200507.